Ventyx Biosciences (VTYX) Earnings
Price: $1.00
Market Cap: $71.13M
Market Cap: $71.13M
Revenue (TTM): $-
Net Income: $-135.12M
Net Income: $-135.12M
P/E Ratio: -0.51
EPS (TTM): $-1.97
EPS (TTM): $-1.97
Earnings Dates
Ventyx Biosciences (VTYX) reports its earnings quarterly. Here are the key details:
Next Earnings Date
- Date: May 08, 2025
- Time of Day: Before Market Open
- Estimated EPS: $-0.48
Last Earnings Report
- Date: February 27, 2025
- EPS: $-0.41
- EPS Estimate: $-0.54
Ventyx Biosciences's next earnings report is scheduled for May 08, 2025.
In its last earnings report on February 27, 2025, Ventyx Biosciences reported earnings per share (EPS) of $-0.41, compared to an estimated EPS of $-0.54. The company reported revenue of $-, compared to an estimated revenue of $-.
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2024 | 2024-05-09 | $-0.67 | $-0.62 |
| Read Transcript | Q2 | 2023 | 2023-08-13 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-05-14 | N/A | N/A |
| Read Transcript | Q4 | 2022 | 2023-03-23 | $-0.59 | $-0.62 |
| Read Transcript | Q3 | 2022 | 2022-11-06 | N/A | N/A |
| Read Transcript | Q2 | 2022 | 2022-08-16 | N/A | N/A |
| Read Transcript | Q1 | 2022 | 2022-05-13 | N/A | N/A |
Earnings History
| Date | EPS | EPS Estimate | Revenue | Revenue Estimate |
|---|---|---|---|---|
| February 27, 2025 | $-0.41 | $-0.54 | $- | $- |
| November 07, 2024 | $-0.50 | $-0.48 | $- | $- |
| August 08, 2024 | $-0.45 | $-0.57 | $- | $- |
| May 09, 2024 | $-0.62 | $-0.67 | $- | $- |
| February 27, 2024 | $-0.79 | $-0.78 | $1.08M | $- |
| November 09, 2023 | $-0.92 | $-0.85 | $- | $- |
| August 10, 2023 | $-0.91 | $-0.71 | $- | $- |
| May 11, 2023 | $-0.68 | $-0.64 | $- | $- |
| March 23, 2023 | $-0.62 | $-0.59 | $- | $- |
| November 03, 2022 | $-0.59 | $-0.45 | $- | $- |
| August 15, 2022 | $-0.39 | $-0.47 | $- | $- |
| May 12, 2022 | $-0.45 | $-0.37 | $- | $- |
| March 23, 2022 | $-0.36 | $-1.00 | $- | $- |
| November 17, 2021 | $-3.17 | $-0.36 | $- | $- |
| October 21, 2021 | $-0.74 | $ | $- | $- |
| March 31, 2021 | $-1.78 | $ | $- | $- |
| December 30, 2020 | $-0.79 | $ | $- | $- |
| September 29, 2020 | $-0.34 | $ | $- | $- |
| June 29, 2020 | $-1.10 | $ | $- | $- |
Annual Earnings
Annual Revenue
$-
Fiscal Year 2024Annual Net Income
$-135.12M
Fiscal Year 2024Annual EPS
$-1.97
Fiscal Year 2024Quarterly Earnings
Revenue
$-
Quarter Ending December 31, 2024Net Income
$-29.35M
Quarter Ending December 31, 2024EPS
$-0.43
Quarter Ending December 31, 2024Earnings Metrics
Earnings Yield
-90.10%
Year Ending December 31, 2024P/E Ratio
-1.11
Year Ending December 31, 2024Revenue Per Share
$0.00
Year Ending December 31, 2024Earnings Yield (TTM)
-197.32%
Trailing Twelve MonthsP/E Ratio (TTM)
-0.51
Trailing Twelve MonthsRevenue Per Share (TTM)
$0.00
Trailing Twelve MonthsFrequently Asked Questions
Ventyx Biosciences's next earnings date is scheduled for May 08, 2025. The earnings call is expected to take place before market open.
In its last earnings report on February 27, 2025, Ventyx Biosciences reported earnings per share (EPS) of $-0.41, compared to an estimated EPS of $-0.54. The company reported revenue of $-, compared to an estimated revenue of $-.
Ventyx Biosciences's current Price-to-Earnings (P/E) ratio is -1.11. The trailing twelve months (TTM) P/E ratio is -0.51. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.
For the fiscal year ending December 31, 2024, Ventyx Biosciences reported total revenue of $- and net income of $-135.12M. This represents a net profit margin of 0.
Ventyx Biosciences's earnings yield is -90.10%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.
Ventyx Biosciences's return on equity (ROE) is -53.19%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.
Ventyx Biosciences's gross profit margin is 0.00%. This indicates that for every dollar of revenue, the company retains $0.00 as gross profit after accounting for the cost of goods sold.
Related Metrics
Explore detailed financial metrics and analysis for VTYX.